Peripheral Vascular Devices Market - Global Forecast to 2029
商品番号 : SMB-9682
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年10月 |
| ページ数 | 324 |
| 図表数 | 417 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global Peripheral vascular devices market is projected to reach USD 14.73 billion by 2029 from USD 11.43 billion in 2024, at a CAGR of 5.2% from 2024 to 2029.
世界の末梢血管デバイス市場は、2024年から2029年までCAGR 5.2%で、2024年の114億3,000万米ドルから2029年までに147億3,000万米ドルに達すると予測されています。
The market for peripheral vascular devices is sharply increasing in view of an increased prevalence of vascular diseases such as PAD and DVT. Other key drivers for this expansion are an aging population base, increased adoption of less-invasive procedures, and advancements in vascular technology in stents, angioplasty balloons, and catheters. Increased awareness about timely diagnosis and treatment options and supportive initiatives from the government further increase market demand. Improvement in global healthcare infrastructure and an increased number of specialized vascular clinics are adding to upward movement of the market.
“By type segment Angioplasty stent to account for the largest share during the forecast period”
The peripheral vascular devices market offers a higher share of stents used in the treatment of angioplasty mainly because stenting is vital in managing diseases such as PAD and CAD. Stents are designed to give long-term vessel support where by the lumen of the arteries needs to be maintained after having a balloon angioplasty. Unlike balloons or catheters, stents are not used only during procedures; they are a permanent solution to the narrowing of an artery, decreasing the chances of restenosis. Technological advancements employing drug-eluting stents (DES) and bioresorbable stents have enhanced the capability of stents by lowering complications and yielding a better prognosis in the long term, therefore making it highly popular.
Stents are also increasingly gaining popularity because they are minimally invasive, where time towards recovery by patients and even the number of days spent in hospitals can be reduced compared to EVAR, or Endovascular Aneurysm Repair traditional surgical methods. Moreover, since the incidence of cardiovascular diseases and pay policies on stent procedures are rapidly moving in a healthy and benign direction, stent stints take the lead. Moreover, given the large geriatric population, where revascularization needs keep soaring, angioplasty stents remain the market leader for peripheral vascular devices.
“APAC is estimated to register the highest CAGR during the forecast period.”
The Peripheral vascular devices market is divided into Five regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific region witnessed the highest CAGR during the forecast period. Many APAC countries, including Japan, South Korea, and China, are witnessing demographic shifts as their populations age. The increasing diabetic population and increase in obesity due to sedentary lifestyles reassesses also driving the growth of peripheral vascular devices in the APAC region.
The breakdown of the profile of primary participants in the peripheral vascular devices market:
- By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
- By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
- By Region: North America – 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5%
List of Companies Profiled in the Report
- Boston scientific corporation(U.S)
- Medtronic (U.S)
- Abbott (U.S)
- Becton, Dickinson, and Company(U.S)
- Terumo Corporation (Japan)
- B. Braun Melsungen AG(Germany)
- Merit medical systems(U.S)
- Penumbra, inc.(U.S)
- Koninklijke Philips N.V..(Japan)
Research Coverage
This report studies the Peripheral vascular devices market based on type and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total Peripheral vascular devices market. The report forecasts the revenue of the market segments to five major regions.
Reasons to Buy the Report
This report also includes.
- Analysis of key drivers (technological advancements), restraints (Cost of the system), challenges (regulatory policies), and opportunities (Increase in minimally invasive procedures) contributing to the growth of the Peripheral vascular devices market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Peripheral vascular devices market.
- Market Development: Comprehensive information on the lucrative emerging markets type and region.
- Market Diversification: Exhaustive information about the growing geographies, recent developments, and investments in the Peripheral vascular devices market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Peripheral vascular devices market.
Table of Contents
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 MARKET SCOPE 29
1.3.1 MARKET SEGMENTATION 29
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 30
1.3.4 CURRENCY CONSIDERED 30
1.4 LIMITATIONS 31
1.5 MARKET STAKEHOLDERS 31
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
2.1.2.1 Key data from primary sources 37
2.1.2.2 Key industry insights 37
2.2 MARKET SIZE ESTIMATION 38
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 43
2.4 MARKET SHARE ANALYSIS 44
2.5 STUDY ASSUMPTIONS 44
2.6 RISK ASSESSMENT 44
2.7 RESEARCH LIMITATIONS 45
2.7.1 METHODOLOGY-RELATED LIMITATIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 PERIPHERAL VASCULAR DEVICES MARKET OVERVIEW 51
4.2 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE AND COUNTRY (2023) 52
4.3 PERIPHERAL VASCULAR DEVICES MARKET: GEOGRAPHIC SNAPSHOT 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
5.2.1 DRIVERS 54
5.2.1.1 Rapid growth in geriatric population and subsequent increase in disease prevalence 54
5.2.1.2 Favorable reimbursement scenario for procedures 54
5.2.1.3 Increased prevalence of diabetes 55
5.2.1.4 Rising rate of tobacco consumption 56
5.2.1.5 Growing incidence of obesity 56
5.2.2 OPPORTUNITIES 57
5.2.2.1 High growth potential in emerging markets 57
5.2.3 CHALLENGES 58
5.2.3.1 Availability of alternative treatments 58
5.2.3.2 Dearth of skilled professionals with expertise in peripheral vascular devices 58
5.2.3.3 Product failures and recalls 58
5.3 INDUSTRY TRENDS 59
5.4 ECOSYSTEM ANALYSIS 59
5.5 VALUE CHAIN ANALYSIS 60
5.6 SUPPLY CHAIN ANALYSIS 61
5.7 PORTER’S FIVE FORCE ANALYSIS 62
5.7.1 THREAT OF NEW ENTRANTS 63
5.7.2 THREAT OF SUBSTITUTES 63
5.7.3 BARGAINING POWER OF SUPPLIERS 63
5.7.4 BARGAINING POWER OF BUYERS 63
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 63
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 64
5.8.1 KEY STAKEHOLDERS 64
5.8.2 BUYING CRITERIA 65
5.9 TECHNOLOGY ANALYSIS 66
5.9.1 KEY TECHNOLOGIES 66
5.9.1.1 Drug-eluting stents 66
5.9.1.2 Atherectomy devices 66
5.9.2 COMPLEMENTARY TECHNOLOGIES 66
5.9.2.1 Intravascular ultrasound 66
5.9.2.2 Optical coherence tomography 66
5.9.3 ADJACENT TECHNOLOGIES 66
5.9.3.1 Remote patient monitoring 66
5.10 REGULATORY LANDSCAPE 67
5.10.1 REGULATORY ANALYSIS 67
5.10.1.1 North America 67
5.10.1.1.1 US 67
5.10.1.1.2 Canada 67
5.10.1.2 Europe 68
5.10.1.3 Asia Pacific 68
5.10.1.3.1 Japan 68
5.10.1.3.2 China 68
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
5.11 TRADE ANALYSIS 71
5.11.1 IMPORT DATA 72
5.11.2 EXPORT DATA 73
5.12 PRICING ANALYSIS 73
5.12.1 AVERAGE SELLING PRICE TREND, BY REGION 74
5.12.2 AVERAGE SELLING PRICE, BY KEY PLAYERS 74
5.13 REIMBURSEMENT ANALYSIS 75
5.14 PATENT ANALYSIS 78
5.14.1 PATENT PUBLICATION TRENDS 78
5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 79
5.15 KEY CONFERENCES AND EVENTS, 2024–2025 80
5.16 CASE STUDIES 81
5.16.1 CASE STUDY 1: DRUG-COATED BALLOON HELPING IN REDUCING RESTENOSIS 81
5.16.2 CASE STUDY 2: IMPROVED OUTCOMES WITH TERUMO’S MISAGO STENT 81
5.17 UNMET NEEDS AND END-USER EXPECTATIONS 82
5.17.1 UNMET NEEDS 82
5.17.2 END-USER EXPECTATIONS 82
5.18 INVESTMENT & FUNDING SCENARIO 83
5.19 IMPACT OF AI ON PERIPHERAL VASCULAR DEVICES MARKET 84
6 PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE 86
6.1 INTRODUCTION 87
7 ANGIOPLASTY STENTS MARKET, BY TYPE 88
7.1 INTRODUCTION 89
7.2 DRUG-ELUTING STENTS 91
7.2.1 DRUG-ELUTING STENTS TO WITNESS HIGHER ADOPTION 91
7.3 BARE-METAL STENTS 93
7.3.1 BARE-METAL STENTS, BY DELIVERY PLATFORM 95
7.3.1.1 Balloon-expandable stents 95
7.3.1.1.1 Better radial strength and ease of deployment to drive usage 95
7.3.1.2 Self-expandable stents 96
7.3.1.2.1 Flexibility, tolerance, and support for vessel movement and compression to propel market 96
8 ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS MARKET, BY TYPE 98
8.1 INTRODUCTION 99
8.2 ABDOMINAL AORTIC ANEURYSM STENT GRAFTS 100
8.2.1 RISING PREVALENCE AND NEED FOR TREATMENT TO DRIVE MARKET 100
8.3 THORACIC AORTIC ANEURYSM STENT GRAFTS 102
8.3.1 INCREASING INCIDENCE OF THORACIC AORTIC ANEURYSMS TO PROPEL ADOPTION 102
9 CATHETERS MARKET, BY TYPE 103
9.1 INTRODUCTION 104
9.2 ANGIOGRAPHY CATHETERS 105
9.2.1 ANGIOGRAPHY CATHETERS TO DOMINATE CATHETERS MARKET 105
9.3 GUIDING CATHETERS 107
9.3.1 GROWING NUMBER OF TARGET PROCEDURES TO DRIVE MARKET 107
9.4 IVUS/OCT CATHETERS 108
9.4.1 IVUS/OCT CATHETERS SEGMENT TO REGISTER HIGHEST GROWTH 108
10 INFERIOR VENA CAVA FILTERS MARKET, BY TYPE 110
10.1 INTRODUCTION 111
10.2 RETRIEVABLE FILTERS 113
10.2.1 RETRIEVABLE FILTERS SEGMENT TO REGISTER HIGHER GROWTH 113
10.3 PERMANENT FILTERS 114
10.3.1 RISKS ASSOCIATED WITH PERMANENT FILTERS TO HAMPER SALES 114
11 ANGIOPLASTY BALLOONS MARKET, BY TYPE 115
11.1 INTRODUCTION 116
11.2 OLD/NORMAL BALLOONS 117
11.2.1 OLD/NORMAL BALLOONS TO DOMINATE ANGIOPLASTY BALLOONS MARKET 117
11.3 DRUG-ELUTING BALLOONS 119
11.3.1 DRUG-ELUTING BALLOONS TO WITNESS HIGHEST GROWTH 119
11.4 CUTTING & SCORING BALLOONS 121
11.4.1 PREFERENCE FOR MEDICATION AS PRIMARY TREATMENT FOR ATHEROSCLEROSIS TO RESTRAIN ADOPTION 121
12 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 123
12.1 INTRODUCTION 124
12.2 ATHERECTOMY DEVICES 126
12.2.1 INCREASING INCIDENCE OF ATHEROSCLEROSIS TO DRIVE MARKET 126
12.3 THROMBECTOMY DEVICES 127
12.3.1 GROWING DVT INCIDENCE TO DRIVE ADOPTION OF THROMBECTOMY DEVICES 127
13 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 129
13.1 INTRODUCTION 130
13.2 EMBOLIC PROTECTION DEVICES 130
13.2.1 INVESTMENTS IN TECHNOLOGICAL ADVANCEMENTS AND GROWING REGULATORY APPROVALS TO DRIVE MARKET 130
13.3 CHRONIC TOTAL OCCLUSION DEVICES 132
13.3.1 RISING SUPPORT FOR DEVICE DEVELOPMENT TO DRIVE MARKET 132
14 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE 134
14.1 INTRODUCTION 135
14.2 GUIDEWIRES 137
14.2.1 GUIDEWIRES TO HOLD LARGEST MARKET SHARE 137
14.3 VASCULAR CLOSURE DEVICES 138
14.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 138
14.4 INTRODUCER SHEATHS 140
14.4.1 POTENTIAL FOR REDUCING ARTERIAL DAMAGE TO DRIVE ADOPTION 140
14.5 BALLOON INFLATION DEVICES 141
14.5.1 INTEGRATED TECHNOLOGIES AND RISING NUMBER OF TARGET PROCEDURES TO PROPEL ADOPTION 141
15 PERIPHERAL VASCULAR DEVICES MARKET, BY REGION 142
15.1 INTRODUCTION 143
15.2 NORTH AMERICA 144
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 145
15.2.2 US 148
15.2.2.1 Favorable reimbursement scenario to contribute to growth 148
15.2.3 CANADA 152
15.2.3.1 Increasing cases of chronic conditions to fuel market 152
15.3 EUROPE 155
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 155
15.3.2 GERMANY 159
15.3.2.1 Statutory health insurance policy to support growth 159
15.3.3 FRANCE 162
15.3.3.1 Growing geriatric population to drive market 162
15.3.4 UK 166
15.3.4.1 Increasing volume of coronary angioplasty procedures to sustain growth 166
15.3.5 SPAIN 169
15.3.5.1 Growing cases of diabetes and obesity to boost market 169
15.3.6 ITALY 173
15.3.6.1 Increasing prevalence of atherosclerotic cardiovascular disease to spur growth 173
15.3.7 REST OF EUROPE 176
15.4 ASIA PACIFIC 180
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 180
15.4.2 JAPAN 185
15.4.2.1 Large geriatric population to ensure sustained demand 185
15.4.3 CHINA 188
15.4.3.1 Growing incidence of lifestyle diseases to fuel market 188
15.4.4 INDIA 191
15.4.4.1 Rising prevalence of target diseases and growing healthcare expenditure to propel market 191
15.4.5 AUSTRALIA 195
15.4.5.1 High prevalence of cardiovascular and peripheral artery diseases to drive market 195
15.4.6 SOUTH KOREA 198
15.4.6.1 Rising rates of chronic diseases to boost market 198
15.4.7 REST OF ASIA PACIFIC 202
15.5 LATIN AMERICA 205
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 205
15.5.2 BRAZIL 208
15.5.2.1 Rising healthcare expenditure to aid growth 208
15.5.3 MEXICO 212
15.5.3.1 Increasing prevalence of cardiovascular diseases to spur growth 212
15.5.4 COLOMBIA 215
15.5.4.1 Growing incidence of peripheral artery diseases to expedite growth 215
15.5.5 ARGENTINA 218
15.5.5.1 Increasing prevalence of peripheral artery diseases to support market growth 218
15.5.6 REST OF LATIN AMERICA 221
15.6 MIDDLE EAST & AFRICA 224
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 225
15.6.2 GCC COUNTRIES 228
15.6.2.1 Rising cases of hypertension and associated cardiovascular diseases to drive market 228
15.6.3 REST OF MIDDLE EAST & AFRICA 231
16 COMPETITIVE LANDSCAPE 235
16.1 INTRODUCTION 235
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 235
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 235
16.3 REVENUE ANALYSIS 236
16.4 MARKET SHARE ANALYSIS 237
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 239
16.5.1 STARS 239
16.5.2 EMERGING LEADERS 239
16.5.3 PERVASIVE PLAYERS 239
16.5.4 PARTICIPANTS 239
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 241
16.5.5.1 Company footprint 241
16.5.5.2 Type footprint 242
16.5.5.3 Region footprint 243
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 244
16.6.1 PROGRESSIVE COMPANIES 244
16.6.2 DYNAMIC COMPANIES 244
16.6.3 RESPONSIVE COMPANIES 244
16.6.4 STARTING BLOCKS 244
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 246
16.7 BRAND/PRODUCT COMPARISON 247
16.8 COMPANY VALUATION AND FINANCIAL METRICS 248
16.8.1 FINANCIAL METRICS 248
16.8.2 COMPANY VALUATION 248
16.9 COMPETITIVE SCENARIO 249
16.9.1 PRODUCT LAUNCHES AND APPROVALS 249
16.9.2 DEALS 250
17 COMPANY PROFILES 252
17.1 KEY PLAYERS 252
17.1.1 BOSTON SCIENTIFIC CORPORATION 252
17.1.1.1 Business overview 252
17.1.1.2 Products offered 253
17.1.1.3 Recent developments 255
17.1.1.3.1 Product approvals 255
17.1.1.3.2 Deals 256
17.1.1.3.3 Other developments 256
17.1.1.4 MnM view 257
17.1.1.4.1 Right to win 257
17.1.1.4.2 Strategic choices 257
17.1.1.4.3 Weaknesses and competitive threats 257
17.1.2 MEDTRONIC 258
17.1.2.1 Business overview 258
17.1.2.2 Products offered 259
17.1.2.3 Recent developments 261
17.1.2.3.1 Product approvals 261
17.1.2.3.2 Deals 262
17.1.2.4 MnM view 262
17.1.2.4.1 Right to win 262
17.1.2.4.2 Strategic choices 262
17.1.2.4.3 Weaknesses and competitive threats 262
17.1.3 ABBOTT 263
17.1.3.1 Business overview 263
17.1.3.2 Products offered 264
17.1.3.3 Recent developments 266
17.1.3.3.1 Product launches 266
17.1.3.3.2 Deals 266
17.1.3.4 MnM view 266
17.1.3.4.1 Right to win 266
17.1.3.4.2 Strategic choices made 266
17.1.3.4.3 Weaknesses and competitive threats 267
17.1.4 BECTON, DICKINSON AND COMPANY 268
17.1.4.1 Business overview 268
17.1.4.2 Products offered 269
17.1.4.3 Recent developments 271
17.1.4.3.1 Product launches and approvals 271
17.1.4.3.2 Deals 272
17.1.4.3.3 Other developments 272
17.1.4.4 MnM view 273
17.1.4.4.1 Right to win 273
17.1.4.4.2 Strategic choices 273
17.1.4.4.3 Weaknesses and competitive threats 273
17.1.5 TERUMO CORPORATION 274
17.1.5.1 Business overview 274
17.1.5.2 Products offered 275
17.1.5.3 Recent developments 276
17.1.5.3.1 Product launches 276
17.1.5.4 MnM view 277
17.1.5.4.1 Right to win 277
17.1.5.4.2 Strategic choices 277
17.1.5.4.3 Weaknesses and competitive threats 277
17.1.6 B. BRAUN SE 278
17.1.6.1 Business overview 278
17.1.6.2 Products offered 279
17.1.7 MERIT MEDICAL SYSTEMS 281
17.1.7.1 Business overview 281
17.1.7.2 Products offered 282
17.1.7.3 Recent developments 283
17.1.7.3.1 Product launches 283
17.1.8 PENUMBRA, INC. 284
17.1.8.1 Business overview 284
17.1.8.2 Products offered 285
17.1.8.3 Recent developments 286
17.1.8.3.1 Product launches and approvals 286
17.1.9 KONINKLIJKE PHILIPS NV 287
17.1.9.1 Business overview 287
17.1.9.2 Products offered 288
17.1.9.3 Recent developments 289
17.1.9.3.1 Product approvals 289
17.1.9.3.2 Deals 289
17.1.10 STRYKER 290
17.1.10.1 Business overview 290
17.1.10.2 Products offered 291
17.1.11 CORDIS 293
17.1.11.1 Business overview 293
17.1.11.2 Products offered 293
17.1.11.3 Recent developments 295
17.1.11.3.1 Product approvals 295
17.1.11.3.2 Other developments 295
17.1.12 COOK 296
17.1.12.1 Business overview 296
17.1.12.2 Products offered 296
17.1.12.3 Recent developments 298
17.1.12.3.1 Deals 298
17.1.13 W. L. GORE & ASSOCIATES, INC. 299
17.1.13.1 Business overview 299
17.1.13.2 Products offered 299
17.1.13.3 Recent developments 301
17.1.13.3.1 Product approvals 301
17.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD. 302
17.1.14.1 Business overview 302
17.1.14.2 Products offered 302
17.1.15 IVASCULAR 303
17.1.15.1 Business overview 303
17.1.15.2 Products offered 303
17.1.16 BIOTRONIK 304
17.1.16.1 Business overview 304
17.1.16.2 Products offered 304
17.1.16.3 Recent developments 305
17.1.16.3.1 Product launches 305
17.1.17 ENDOLOGIX 306
17.1.17.1 Business overview 306
17.1.17.2 Products offered 306
17.1.18 ENDOCOR GMBH & CO., KG 307
17.1.18.1 Business overview 307
17.1.18.2 Products offered 307
17.2 OTHER PLAYERS 308
17.2.1 MERIL LIFE SCIENCES PVT. LTD. 308
17.2.2 ALVIMEDICA 309
17.2.3 CARDIONOVUM GMBH 310
17.2.4 SMT 310
17.2.5 MEDINOL 311
17.2.6 ANDRAMED GMBH 311
17.2.7 REX MEDICAL 312
17.2.8 QMD INC. 312
17.2.9 BROSMED MEDICAL CO., LTD. 313
17.2.10 ELIXIR MEDICAL 314
18 APPENDIX 315
18.1 DISCUSSION GUIDE 315
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 320
18.3 CUSTOMIZATION OPTIONS 322
18.4 RELATED REPORTS 322
18.5 AUTHOR DETAILS 323
LIST OF TABLES
TABLE 1 STANDARD CURRENCY CONVERSION RATES 31
TABLE 2 PERIPHERAL VASCULAR DEVICES MARKET: ASSUMPTION ANALYSIS 44
TABLE 3 PERIPHERAL VASCULAR DEVICES MARKET: RISK ASSESSMENT ANALYSIS 44
TABLE 4 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030 54
TABLE 5 US: REIMBURSEMENT FOR PERIPHERAL VASCULAR PROCEDURES 55
TABLE 6 DIABETIC POPULATION, BY REGION, 2019 VS. 2030 55
TABLE 7 TOP 10 COUNTRIES WITH HIGHEST SMOKING RATE (2021) 56
TABLE 8 OBESITY RATE, BY COUNTRY (2022) 57
TABLE 9 PERIPHERAL VASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 63
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PERIPHERAL
VASCULAR DEVICES 64
TABLE 11 KEY BUYING CRITERIA FOR PERIPHERAL VASCULAR DEVICES 65
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 69
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 69
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 70
TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 70
TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 71
TABLE 17 HS CODES FOR PERIPHERAL VASCULAR DEVICES MARKET 71
TABLE 18 IMPORT DATA FOR HS CODE 901839, BY COUNTRY,
2019–2023 (USD THOUSAND) 72
TABLE 19 EXPORT DATA FOR HS CODE 901839, BY COUNTRY,
2019–2023 (USD THOUSAND) 73
TABLE 20 AVERAGE SELLING PRICE TREND OF PERIPHERAL VASCULAR DEVICES,
BY REGION, BY TYPE 2021–2023 (USD) 74
TABLE 21 AVERAGE SELLING PRICE OF PERIPHERAL VASCULAR DEVICE,
BY KEY PLAYER (2023) 74
TABLE 22 REIMBURSEMENT ANALYSIS FOR PERIPHERAL VASCULAR PROCEDURES 75
TABLE 23 DETAILED LIST OF KEY CONFERENCES AND EVENTS 80
TABLE 24 UNMET NEEDS: PERIPHERAL VASCULAR DEVICES MARKET 82
TABLE 25 END-USER EXPECTATIONS: PERIPHERAL VASCULAR DEVICES MARKET 82
TABLE 26 AI INTEGRATION: PERIPHERAL VASCULAR DEVICES MARKET 84
TABLE 27 PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 87
TABLE 28 ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 89
TABLE 29 ANGIOPLASTY STENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 90
TABLE 30 DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 31 BARE-METAL STENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 32 BARE-METAL STENTS MARKET, BY DELIVERY PLATFORM,
2022–2029 (USD MILLION) 95
TABLE 33 BALLOON-EXPANDABLE STENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 96
TABLE 34 SELF-EXPANDABLE STENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 35 EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 99
TABLE 36 EVAR STENT GRAFTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 37 AAA STENT GRAFTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 38 TAA STENT GRAFTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 39 CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 104
TABLE 40 CATHETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 41 ANGIOGRAPHY CATHETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 42 GUIDING CATHETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 43 IVUS/OCT CATHETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 44 INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 111
TABLE 45 INFERIOR VENA CAVA FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 46 RETRIEVABLE INFERIOR VENA CAVA FILTERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 113
TABLE 47 PERMANENT INFERIOR VENA CAVA FILTERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 114
TABLE 48 ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 116
TABLE 49 ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 50 OLD/NORMAL BALLOONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 51 DRUG-ELUTING BALLOONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 52 CUTTING & SCORING BALLOONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 53 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 124
TABLE 54 PLAQUE MODIFICATION DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 55 ATHERECTOMY DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 56 THROMBECTOMY DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 57 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 130
TABLE 58 EMBOLIC PROTECTION DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 131
TABLE 59 CHRONIC TOTAL OCCLUSION DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 60 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 135
TABLE 61 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 136
TABLE 62 GUIDEWIRES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 63 VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 64 INTRODUCER SHEATHS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 65 BALLOON INFLATION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 66 PERIPHERAL VASCULAR DEVICES MARKET, BY REGION,
2022–2029 (USD MILLION) 143
TABLE 67 NORTH AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 145
TABLE 68 NORTH AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 145
TABLE 69 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 146
TABLE 70 NORTH AMERICA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 146
TABLE 71 NORTH AMERICA: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 146
TABLE 72 NORTH AMERICA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 147
TABLE 73 NORTH AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 147
TABLE 74 NORTH AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 147
TABLE 75 NORTH AMERICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 148
TABLE 76 US: MACROECONOMIC INDICATORS 149
TABLE 77 US: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 78 US: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 79 US: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 150
TABLE 80 US: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 150
TABLE 81 US: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 150
TABLE 82 US: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 151
TABLE 83 US: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 151
TABLE 84 US: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 151
TABLE 85 CANADA: MACROECONOMIC INDICATORS 152
TABLE 86 CANADA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 152
TABLE 87 CANADA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 88 CANADA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 89 CANADA: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 90 CANADA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 154
TABLE 91 CANADA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 154
TABLE 92 CANADA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 154
TABLE 93 CANADA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 155
TABLE 94 EUROPE: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 156
TABLE 95 EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 96 EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 97 EUROPE: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 157
TABLE 98 EUROPE: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 157
TABLE 99 EUROPE: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 157
TABLE 100 EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 158
TABLE 101 EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 158
TABLE 102 EUROPE: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 158
TABLE 103 GERMANY: MACROECONOMIC INDICATORS 159
TABLE 104 GERMANY: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 159
TABLE 105 GERMANY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 160
TABLE 106 GERMANY: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 160
TABLE 107 GERMANY: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 160
TABLE 108 GERMANY: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 161
TABLE 109 GERMANY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 161
TABLE 110 GERMANY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 111 GERMANY: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 162
TABLE 112 FRANCE: MACROECONOMIC INDICATORS 163
TABLE 113 FRANCE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 114 FRANCE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 115 FRANCE: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 116 FRANCE: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 117 FRANCE: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 164
TABLE 118 FRANCE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 165
TABLE 119 FRANCE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 120 FRANCE: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 121 UK: MACROECONOMIC INDICATORS 166
TABLE 122 UK: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION 167
TABLE 123 UK: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 124 UK: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 125 UK: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 126 UK: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 127 UK: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 168
TABLE 128 UK: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 129 UK: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 130 SPAIN: MACROECONOMIC INDICATORS 170
TABLE 131 SPAIN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 132 SPAIN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 133 SPAIN: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 134 SPAIN: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 135 SPAIN: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 171
TABLE 136 SPAIN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 172
TABLE 137 SPAIN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 138 SPAIN: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 139 ITALY: MACROECONOMIC INDICATORS 173
TABLE 140 ITALY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 141 ITALY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 142 ITALY: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 143 ITALY: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 144 ITALY: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 175
TABLE 145 ITALY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 175
TABLE 146 ITALY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 147 ITALY: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 176
TABLE 148 REST OF EUROPE: PERCENTAGE OF GERIATRIC POPULATION TO TOTAL POPULATION, BY COUNTRY, 2015 VS. 2030 (MILLION) 177
TABLE 149 REST OF EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 177
TABLE 150 REST OF EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 177
TABLE 151 REST OF EUROPE: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 152 REST OF EUROPE: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 178
TABLE 153 REST OF EUROPE: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 178
TABLE 154 REST OF EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 179
TABLE 155 REST OF EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 156 REST OF EUROPE: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 157 ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 182
TABLE 158 ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 182
TABLE 159 ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 182
TABLE 160 ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 161 ASIA PACIFIC: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 162 ASIA PACIFIC: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 183
TABLE 163 ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 184
TABLE 164 ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 165 ASIA PACIFIC: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 166 JAPAN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 167 JAPAN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 168 JAPAN: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 169 JAPAN: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 170 JAPAN: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 187
TABLE 171 JAPAN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 187
TABLE 172 JAPAN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 173 JAPAN: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 188
TABLE 174 CHINA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION 189
TABLE 175 CHINA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 176 CHINA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 177 CHINA: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 178 CHINA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 190
TABLE 179 CHINA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 190
TABLE 180 CHINA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 181 CHINA: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 182 INDIA: MACROECONOMIC INDICATORS 192
TABLE 183 INDIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 184 INDIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 185 INDIA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 186 INDIA: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 187 INDIA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 193
TABLE 188 INDIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 194
TABLE 189 INDIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 194
TABLE 190 INDIA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 194
TABLE 191 AUSTRALIA: MACROECONOMIC INDICATORS 195
TABLE 192 AUSTRALIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 195
TABLE 193 AUSTRALIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 194 AUSTRALIA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 195 AUSTRALIA: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 196 AUSTRALIA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 197
TABLE 197 AUSTRALIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 197
TABLE 198 AUSTRALIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 199 AUSTRALIA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 198
TABLE 200 SOUTH KOREA: MACROECONOMIC INDICATORS 199
TABLE 201 SOUTH KOREA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 202 SOUTH KOREA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 203 SOUTH KOREA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 204 SOUTH KOREA: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 200
TABLE 205 SOUTH KOREA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 200
TABLE 206 SOUTH KOREA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 201
TABLE 207 SOUTH KOREA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 208 SOUTH KOREA: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 209 REST OF ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 202
TABLE 210 REST OF ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 202
TABLE 211 REST OF ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 212 REST OF ASIA PACIFIC: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 203
TABLE 213 REST OF ASIA PACIFIC: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 203
TABLE 214 REST OF ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 204
TABLE 215 REST OF ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 216 REST OF ASIA PACIFIC: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 217 LATIN AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 205
TABLE 218 LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 206
TABLE 219 LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 206
TABLE 220 LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 221 LATIN AMERICA: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 222 LATIN AMERICA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 223 LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 224 LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 225 LATIN AMERICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 226 BRAZIL: MACROECONOMIC INDICATORS 209
TABLE 227 BRAZIL: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 228 BRAZIL: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 229 BRAZIL: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 230 BRAZIL: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 231 BRAZIL: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 210
TABLE 232 BRAZIL: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 211
TABLE 233 BRAZIL: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 234 BRAZIL: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 211
TABLE 235 MEXICO: MACROECONOMIC INDICATORS 212
TABLE 236 MEXICO: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 237 MEXICO: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 238 MEXICO: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 239 MEXICO: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 214
TABLE 240 MEXICO: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 214
TABLE 241 MEXICO: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 214
TABLE 242 MEXICO: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 243 MEXICO: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 244 COLOMBIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 216
TABLE 245 COLOMBIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 246 COLOMBIA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 247 COLOMBIA: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 248 COLOMBIA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 217
TABLE 249 COLOMBIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 217
TABLE 250 COLOMBIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 251 COLOMBIA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 218
TABLE 252 ARGENTINA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 219
TABLE 253 ARGENTINA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 254 ARGENTINA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 255 ARGENTINA: EVAR STENT GRAFTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 256 ARGENTINA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 220
TABLE 257 ARGENTINA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 220
TABLE 258 ARGENTINA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 259 ARGENTINA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 221
TABLE 260 REST OF LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 222
TABLE 261 REST OF LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 222
TABLE 262 REST OF LATIN AMERICA: CATHETERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 222
TABLE 263 REST OF LATIN AMERICA: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 223
TABLE 264 REST OF LATIN AMERICA: INFERIOR VENA CAVA FILTERS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 265 REST OF LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 266 REST OF LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 267 REST OF LATIN AMERICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 268 MIDDLE EAST & AFRICA: PERIPHERAL VASCULAR DEVICES MARKET,
BY REGION, 2022–2029 (USD MILLION) 225
TABLE 269 MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 225
TABLE 270 MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 226
TABLE 271 MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 226
TABLE 272 MIDDLE EAST & AFRICA: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 226
TABLE 273 MIDDLE EAST & AFRICA: INFERIOR VENA CAVA FILTERS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 274 MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 275 MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 276 MIDDLE EAST & AFRICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 277 GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 229
TABLE 278 GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 229
TABLE 279 GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 280 GCC COUNTRIES: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 230
TABLE 281 GCC COUNTRIES: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 230
TABLE 282 GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 230
TABLE 283 GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 284 GCC COUNTRIES: OTHER PERIPHERAL VASCULAR DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 285 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 286 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 287 REST OF MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 232
TABLE 288 REST OF MIDDLE EAST & AFRICA: EVAR STENT GRAFTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 233
TABLE 289 REST OF MIDDLE EAST & AFRICA: INFERIOR VENA CAVA FILTERS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 290 REST OF MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 291 REST OF MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 292 REST OF MIDDLE EAST & AFRICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 293 PERIPHERAL VASCULAR DEVICES MARKET: DEGREE OF COMPETITION 238
TABLE 294 PERIPHERAL VASCULAR DEVICES MARKET: TYPE FOOTPRINT 242
TABLE 295 PERIPHERAL VASCULAR DEVICES MARKET: REGION FOOTPRINT 243
TABLE 296 PERIPHERAL VASCULAR DEVICES MARKET: KEY STARTUPS/SMES 246
TABLE 297 PERIPHERAL VASCULAR DEVICES MARKET: COMPETITIVE BENCHMARKING
OF START-UPS/SMES 247
TABLE 298 PERIPHERAL VASCULAR DEVICES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2024 249
TABLE 299 PERIPHERAL VASCULAR DEVICES MARKET: DEALS, JANUARY 2021–AUGUST 2024 250
TABLE 300 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 252
TABLE 301 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 253
TABLE 302 BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS,
JANUARY 2021– AUGUST 2024 255
TABLE 303 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–AUGUST 2024 256
TABLE 304 BOSTON SCIENTIFIC CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2021– AUGUST 2024 256
TABLE 305 MEDTRONIC: COMPANY OVERVIEW 258
TABLE 306 MEDTRONIC: PRODUCTS OFFERED 259
TABLE 307 MEDTRONIC: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024 261
TABLE 308 MEDTRONIC: DEALS, JANUARY 2021–AUGUST 2024 262
TABLE 309 ABBOTT: COMPANY OVERVIEW 263
TABLE 310 ABBOTT: PRODUCTS OFFERED 264
TABLE 311 ABBOTT: PRODUCT LAUNCHES, JANUARY 2021–AUGUST 2024 266
TABLE 312 ABBOTT: DEALS, JANUARY 2021–AUGUST 2024 266
TABLE 313 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 268
TABLE 314 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 269
TABLE 315 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2024 271
TABLE 316 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–AUGUST 2024 272
TABLE 317 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS,
JANUARY 2021– AUGUST 2024 272
TABLE 318 TERUMO CORPORATION: COMPANY OVERVIEW 274
TABLE 319 TERUMO CORPORATION: PRODUCTS OFFERED 275
TABLE 320 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–AUGUST 2024 276
TABLE 321 B. BRAUN SE: COMPANY OVERVIEW 278
TABLE 322 B. BRAUN SE: PRODUCTS OFFERED 279
TABLE 323 MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW 281
TABLE 324 MERIT MEDICAL SYSTEMS: PRODUCTS OFFERED 282
TABLE 325 MERIT MEDICAL SYSTEMS: PRODUCT LAUNCHES, JANUARY 2021–AUGUST 2024 283
TABLE 326 PENUMBRA, INC.: COMPANY OVERVIEW 284
TABLE 327 PENUMBRA, INC.: PRODUCTS OFFERED 285
TABLE 328 PENUMBRA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–
AUGUST 2024 286
TABLE 329 KONINKLIJKE PHILIPS NV: COMPANY OVERVIEW 287
TABLE 330 KONINKLIJKE PHILIPS NV: PRODUCTS OFFERED 288
TABLE 331 KONINKLIJKE PHILIPS NV: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024 289
TABLE 332 KONINKLIJKE PHILIPS NV: DEALS, JANUARY 2021–AUGUST 2024 289
TABLE 333 STRYKER: COMPANY OVERVIEW 290
TABLE 334 STRYKER: PRODUCTS OFFERED 291
TABLE 335 CORDIS: COMPANY OVERVIEW 293
TABLE 336 CORDIS: PRODUCTS OFFERED 293
TABLE 337 CORDIS: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024 295
TABLE 338 CORDIS: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2024 295
TABLE 339 COOK: COMPANY OVERVIEW 296
TABLE 340 COOK: PRODUCTS OFFERED 296
TABLE 341 COOK: DEALS, JANUARY 2021–AUGUST 2024 298
TABLE 342 W. L. GORE & ASSOCIATES, INC.: COMPANY OVERVIEW 299
TABLE 343 W. L. GORE & ASSOCIATES, INC.: PRODUCTS OFFERED 299
TABLE 344 W. L. GORE & ASSOCIATES, INC: PRODUCT APPROVALS, JANUARY 2021–
AUGUST 2024 301
TABLE 345 BIOSENSORS INTERNATIONAL GROUP, LTD.: COMPANY OVERVIEW 302
TABLE 346 BIOSENSORS INTERNATIONAL GROUP, LTD.: PRODUCTS OFFERED 302
TABLE 347 IVASCULAR: COMPANY OVERVIEW 303
TABLE 348 IVASCULAR: PRODUCTS OFFERED 303
TABLE 349 BIOTRONIK: COMPANY OVERVIEW 304
TABLE 350 BIOTRONIK: PRODUCTS OFFERED 304
TABLE 351 BIOTRONIK: PRODUCT LAUNCHES, JANUARY 2021–AUGUST 2024 305
TABLE 352 ENDOLOGIX: COMPANY OVERVIEW 306
TABLE 353 ENDOLOGIX: PRODUCTS OFFERED 306
TABLE 354 ENDOCOR GMBH & CO., KG: COMPANY OVERVIEW 307
TABLE 355 ENDOCOR GMBH & CO., KG: PRODUCTS OFFERED 307
TABLE 356 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW 308
TABLE 357 ALVIMEDICA: COMPANY OVERVIEW 309
TABLE 358 CARDIONOVUM GMBH: COMPANY OVERVIEW 310
TABLE 359 SMT: COMPANY OVERVIEW 310
TABLE 360 MEDINOL: COMPANY OVERVIEW 311
TABLE 361 ANDRAMED GMBH: COMPANY OVERVIEW 311
TABLE 362 REX MEDICAL: COMPANY OVERVIEW 312
TABLE 363 QMD INC.: COMPANY OVERVIEW 312
TABLE 364 BROSMED MEDICAL CO., LTD.: COMPANY OVERVIEW 313
TABLE 365 ELIXIR MEDICAL: COMPANY OVERVIEW 314
LIST OF FIGURES
FIGURE 1 MARKETS COVERED 29
FIGURE 2 RESEARCH DESIGN 33
FIGURE 3 PRIMARY SOURCES 36
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 38
FIGURE 5 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 39
FIGURE 6 TOP-DOWN APPROACH 39
FIGURE 7 MARKET SIZE ESTIMATION: DEMAND-SIDE ASSESSMENT 40
FIGURE 8 PERIPHERAL VASCULAR DEVICES MARKET: CAGR PROJECTIONS (2024–2029) 41
FIGURE 9 DATA TRIANGULATION METHODOLOGY 43
FIGURE 10 ANGIOPLASTY STENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 46
FIGURE 11 EVAR STENT GRAFTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 47
FIGURE 12 INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 47
FIGURE 13 CATHETERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 48
FIGURE 14 ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 48
FIGURE 15 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024 VS.
2029 (USD MILLION) 49
FIGURE 16 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2024 VS. 2029 (USD MILLION) 49
FIGURE 17 GEOGRAPHIC SNAPSHOT OF PERIPHERAL VASCULAR DEVICES MARKET 50
FIGURE 18 GROWING GERIATRIC POPULATION AND RISING INCREASE IN DISEASE PREVALENCE TO DRIVE MARKET 51
FIGURE 19 DRUG-ELUTING STENTS SEGMENT ACCOUNTED FOR LARGEST MARKET
SHARE IN 2023 52
FIGURE 20 JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52
FIGURE 21 PERIPHERAL VASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
FIGURE 22 KEY TRENDS IN MARKET: TECHNOLOGICAL ADVANCEMENTS AND SHIFT TOWARD MINIMALLY INVASIVE SURGERIES 59
FIGURE 23 PERIPHERAL VASCULAR DEVICES MARKET: ECOSYSTEM ANALYSIS 59
FIGURE 24 PERIPHERAL VASCULAR DEVICES MARKET: VALUE CHAIN ANALYSIS 60
FIGURE 25 PERIPHERAL VASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS 62
FIGURE 26 PERIPHERAL VASCULAR DEVICES MARKET: PORTER’S FIVE FORCE ANALYSIS 62
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PERIPHERAL
VASCULAR DEVICES 64
FIGURE 28 KEY BUYING CRITERIA FOR PERIPHERAL VASCULAR DEVICES 65
FIGURE 29 NUMBER OF PATENT PUBLICATIONS (JANUARY 2014─MARCH 2024) 78
FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) PATENTS (JANUARY 2014─ AUGUST 2024) 79
FIGURE 31 PERIPHERAL VASCULAR DEVICES MARKET: INVESTMENT & FUNDING
SCENARIO (2018–2023) 83
FIGURE 32 NORTH AMERICA: PERIPHERAL VASCULAR DEVICES MARKET SNAPSHOT 144
FIGURE 33 ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET SNAPSHOT 181
FIGURE 34 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PERIPHERAL VASCULAR DEVICES MARKET 235
FIGURE 35 REVENUE ANALYSIS FOR KEY PLAYERS IN PERIPHERAL VASCULAR DEVICES MARKET (2019–2023) 236
FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PERIPHERAL VASCULAR DEVICES MARKET (2023) 237
FIGURE 37 PERIPHERAL VASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 240
FIGURE 38 PERIPHERAL VASCULAR DEVICES MARKET: COMPANY FOOTPRINT 241
FIGURE 39 PERIPHERAL VASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 245
FIGURE 40 PERIPHERAL VASCULAR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 247
FIGURE 41 EV/EBITDA OF KEY VENDORS 248
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 248
FIGURE 43 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 253
FIGURE 44 MEDTRONIC: COMPANY SNAPSHOT 259
FIGURE 45 ABBOTT: COMPANY SNAPSHOT 264
FIGURE 46 BECTON, DICKISON AND COMPANY: COMPANY SNAPSHOT 269
FIGURE 47 TERUMO CORPORATION: COMPANY SNAPSHOT 275
FIGURE 48 B. BRAUN SE: COMPANY SNAPSHOT 279
FIGURE 49 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT 282
FIGURE 50 PENUMBRA, INC.: COMPANY SNAPSHOT 285
FIGURE 51 KONINKLIJKE PHILIPS NV: COMPANY SNAPSHOT 288
FIGURE 52 STRYKER: COMPANY SNAPSHOT 291
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 真性乱数生成器（TRNG）市場 – 2030年までの世界予測 2025-03-19
- 米国のヘルスケア/病院フードサービス市場 – 2029年までの予測 2025-03-18
- 圧力トランスミッタ市場 – 2030年までの世界予測 2025-03-18
- 中央ラボサービス/臨床試験ラボサービス市場 – 2030年までの世界予測 2025-03-18
- 空港システム市場 – 2030年までの世界予測 2025-03-17